Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Trial Details

NCT ID

NCT05476796

Phase

PHASE2

Sponsor

UNICANCER

Status

RECRUITING

Cancer Type

Adenocarcinoma Esophageal Cancer

Interventions

• Trifluridine/Tipiracil
• Oxaliplatin
• FOLFOX regimen
• Nivolumab

Locations (sample)

• Amiens, France|49.9,2.3
• Arras, France|50.29301,2.78186
• Avignon, France|43.94834,4.80892
• Beauvais, France|49.43333,2.08333
• Besançon, France|47.24878,6.01815

Key Eligibility Criteria

• Histologically confirmed locally advanced, recurrent or metastatic non resectable adenocarcinoma of the stomach, oesophagus or gastroesophageal jun…
• No dysphagia or difficulty in swallowing.
• No overexpression/amplification of HER2 (IHC 0 or 1+; if IHC is 2+, HIS must be negative). Known combined positive scor (CPS) PD-L1 score (result i…
• At least one evaluable lesion according to RECIST v1.1 outside any previously irradiated area.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.